Aspira Women's Health Inc. · OTC:AWHL

Aspira Women's Health — Vermillion — Investor Presentation (January 2016)

36 slides from Aspira Women's Health's investor presentation, Jan 11, 2016

  1. Slide 1: Informatic Solutions to Personalize Gynecologic Disease Management

    (2 VERMILLION’ Informatic Solutions to Personalize Gynecologic Disease Management $4 ty SO ASPIRA LABS JANUARY 2016 ‘YOUR HEALTH. OUR PASSION.

  2. Slide 2: Forward-Looking Statements

    QVERMILLION" FORWARD-LOOKING STATEMENTS This presentation contains forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995. Words such as “may,” “expects,” “intends,” “anticipates,” “believes,” “estimates,” “plans,” “seeks,” “could,” “should,” “continue,” “will

  3. Slide 3: Company Overview

    Company Overview ° Ticker Symbol: VRML (NASDAQ CM) ¢ Market Cap (12-21-2015): $91.0M - Shares Outstanding (10-31-2015): 52.0M ¢ Cash and Cash Equivalents (9-30-2015): $24.0M ¢ Enterprise Value: $67.0M LQVERMILLION' eas ventan ne Ag tae 3

  4. Slide 4: Vermillion's Focus is Gynecologic Health

    Vermillion’s Focus is Gynecologic Health To be the global leader in personalized medical management of gynecologic health to improve clinical comes for patients, physicians and payers ‘ To aid clinicians in diagnosing women with pelvic mize their care and ultimately save lives, while improving the q

  5. Slide 5: Investment Highlights

    Investment Highlights * First of its kind, FDA-cleared multi-variate technology platform * Target market expanding to >$1 billion with the OVA family of products* * New Management Team in place * Key investor support from Jack W. Schuler and Oracle Investment Management * February 2015 — ASPiRA sale

  6. Slide 6: Vermillion Has a Large Market Opportunity

    Vermillion Has a Large Market Opportunity Benign US healthcare system annually Mass S€°" Non-Gyn spends $22B on endometriosis Hasislosde — care’, $5.1B on Ov Ca care? and cyst $1.2B on PCOS care? benign’ Ovarian } Ovarian ; Pelvic : Pelvic Pelvic Cancer } Cancer ? Masses { Masses Diseases Deaths = 3

  7. Slide 7: Ovarian Cancer - The Size of the Problem

    Ovarian Cancer - The Size of the Problem Ovarian cancer stage at presentation and survival 5-Year Incidence Survival Stagel | I Confined to the ovary 23% 90% Extends to true pelvis 13% 80% Extends beyond the true pelvis 47% 15-20% Distant disease 16% <5% >60% of ovarian cancers are diagnosed at late

  8. Slide 8: Despite This Unmet Clinical Need...

    Despite This Unmet Clinical Ne ..-no solution exists. Current standard of care is inadequate to manage patients and results in poor outcomes and increased costs Clinical findings are inadequate... © Physical exam is specialist-dependent ¢ Imaging is subjective ..as are commonly used biomarkers © CA-

  9. Slide 9: Vermillion's Solution

    Vermillion’s Solution Ova An FDA-cleared liquid biopsy test, which pre-operatively assesses risk of ovarian cancer and helps triage high risk patients The OvaCalc® algorithm combines five biomarker results into a single numerical “test value” related to the probability of malignancy Interpret OVA1 o

  10. Slide 10: Vermillion's Solution: How It is Used in Practice

    Vermillion’s Solution: How It is Used in Practice After Protocol: Before Protocol: Survey 96% cancer detction QVERMILLION Z

  11. Slide 11: Vermillion's Solution: How It is Used in Practice

    Oa Vermillion’s Solution: How It is Used in Practice Or QVERMILLION'

  12. Slide 12: OVA1 vs Standard of Care

    (A1°® vs Standard of Care Q VERMILLION

  13. Slide 13: 85% Reduction

    85% Reduction - 23% 50% 0% CA125-II* Clinical Modified OVA1 OVA1 + Assessment*? ACOG** Clinical Assessment™

  14. Slide 14: Key Publications

    Key Publications Author, ‘Conel le ‘etiee onclusions Effectiveness of amultvarate Ualend, etal. gq) * Fist etal ial of OVANY n= $90 smal University + OVAI detacted 76% of malignancies missed by CA-125 Bisoperstve oF Kentucky _pationts assessment of «= The performance of OVA wes consistent in early-

  15. Slide 15: Publications Drive Standard of Care/Reimbursement

    Publications Drive Standard of Care/Reimbursement iblished Evidence Guidelines Payers Ueland, et al. Obstetrics and Gynecology, 2011 Ne <€ Medicare Bristow, et al. Gynecologic Oncology, 2013 Society of Gynecologic Longoria, et al. Oncology ‘Am J Obstet Gynecol, 2013 “se Position Statements Goodrichr

  16. Slide 16: Intellectual Property

    Intellectual Property Strong IP Protection a * Issued patents covering various ovarian cancer biomarkers ¢ Pending patent applications covering OVA1® and Overa® products Algorithm - kept as trade secret QVERMILLION

  17. Slide 17: Continuing Product Development

    Continuing Product Development Improvement to OVA1's biomarker technology is expected soon... Cva® = Qvera Increased specificity and positive predictive value (PPV), maintaining the sam s 1 NPV as OVA1, more accurately assorting patients for r Expected to be launched in early 2016

  18. Slide 18: Overa - Breakthrough in Ovarian Cancer Management

    Overa® - Breakthrough in Ovarian Cancer Management || Sensitivity | Specificity | PPV | NPV 92% 54% 31% 97% (85.1-96.3) (48.6-58.3) (26.0-37.0) (93.6-98.5) Equal Equal Veracyte* Afirma 92% 52% 32-47% 93-96% QVERMILLION

  19. Slide 19: We Save More Lives and Reduce More Cost

    We Save More Lives and Reduce More Cost By Evolving Our Strategy To radically imprc classifying all f patient care, we have expanded our scope by Ivic mass patients to determine the best disease management care path 500K to 1M pelvic masses diagn Correct referral fc rect treatment ovarian cancer sur

  20. Slide 20: Build on Our Foundation

    Build on Our Foundation To impact this expanded scope, biomarkers alone are limited in terms of needed algorithm development and accuracy Unparalleled Data Registry ei) ral 9 Imaging/ : Clinical Data iran ocahues Biomarkers zg Algorithm Platform QVERMILLION’

  21. Slide 21: Building on Our Foundation - Our Expertise

    g on Our Foundation - Our Exp’ OVA SERIES tb IMAGING Vv FDA Vv Proof of concept studies V Biomarkers V Algorithm development V Multi-center studies VIP ——" PROVEN =» COMPETENCIES QVERMILLION

  22. Slide 22: 250K - 1M TAM

    250K - 1M TAM Rule out; watc surgical choi progression, recurr monitoring 100K - 300K TAM Guided referral $440M - $880M $67M - $200M

  23. Slide 23: The Value of Vermillion

    The Value of Vermillion To Patients (ama) To Providers MY To Payers QVERMILLION® 62015 Vermin ne. igh Rater olution for all Customers « Improve time to Tx * Low risk: peace of mind * High risk: get to the right specialist * Improved differential Dx © Low risk: keep patient ¢ High risk: refer to Gyn

  24. Slide 24: Product Pipeline of ASPiRA Labs

    Product Pipeline of ASPiRA Labs Product | ovat? | Overa | Overan | OVAt | DxA | DxA2 | =a Propoeiion Rule-out, surgical Rule-out, surgical speaist specaist ‘pathway cholce, ‘pathway chotce, Dxor referral referral progression progression" endometriosis Market size! 100-300K 100-300K 250K-1M 250K-1M >

  25. Slide 25: International

    INTERNATIONAL Top down, high-touch approach to IDNs, systems, ACOs Bottom uplow-touch approach to patients, providers — WVDSenice Offering —> *Overa® platform: Roche Cobas 6000 (10,000 installed worldwide) according to itto:/www. cobas,com/home/product/clinical-and-immunochemistry-testing/cobas-6000

  26. Slide 26: Commercialization Strategy

    Commercialization Strategy Payer strategy to increase utilization and average unit price Bn a Seen ease ASEIRA Labs sepisnel lly Sofie referral base (eee tegen Wb ibe fe atient date) Ss / : Hospital stable revenue OB/Gyn Systems / (Customer Account Menagers and Market Development Specialists) Region

  27. Slide 27: OVA1 Coverage YTD - Patient Lives in Millions

    OVA1® Coverage YTD - Patient Lives in Millions Goal: Targeted Growth with Positive Coverage Decisions Target: 2 National 7 Payor 2U = Pots) mo Michigan 4 Arkansas Novitas Rivers ai LQVERMILLION — c2:s verter i red 27

  28. Slide 28: Cost Effectiveness Model Analysis

    Cost Effectiveness Model Analysis ICER OvaA1* ASPiRA ~$1,495 $12,189/QALY' ovat** ASPIRA ~$1,495 $35,094/QALY" BRCA1/2 Myriad Genetics ~$4,040 $36,845/QALY* Oncotype DX Genomic Health ~$4,175 $15,578/QALY? Threshold to be considered cost effective $50,000/QALY Incromental cost-affectiveness ratio (I

  29. Slide 29: Experienced Management Team in Place

    Experienced Management Team in Place Title Experience Valet Palit President and CEO Duanon.gsiems_ LabCorp oe : Donald Munroe, PhD. Cre stintine Offer Zecca | coniye Invitrogen Psanner MDAnderson Judith Wolf, M.D. Chief Medical Officer Ee Set antes Laura Miller SVR Sales Castors Eiparense @HealthTro

  30. Slide 30: 2015 Achievements / 2016 Anticipated Milestones

    2015 Achievements / 2016 Anticipated Milestones U Overa® FDA submission - March 6,2015 Quest settlement and testing services agreement - March 11, 2015 Strategic partnership and quality benchmarking study with Kaiser Permanente (Southem California) announced - April 14, 2015 Disclose Overa data (ASC

  31. Slide 31: -QVERMILLION®

    -QVERMILLION® ¢ Price (maintain / build value) ¢ Sales ramp / penetration (build on existing market share / call point) ¢ Margins (>80% over 2016 - 2019) e Reimbursement - revenue cycle management 31

  32. Slide 32: Vermillion Expects to Be a Market Leader by 2020 / Anticipated Milestones

    Vermillion Expects to Be a Market Leader by 2020 / Anticipated Milestones Volume maltpiors regional lab One See ot validation Studies Ovetapue anticipatory sudies —imaging, {CGN sco, sar ‘Ova symptomindex, ASCO, ACOG HECON, guidelines DxA DxA Overa® — — ———_ validation HECON deared studies studies v

  33. Slide 33: Sustainable Advantages, Tailwinds and Headwinds

    Sustainable Advantages, Tailwinds and Headwinds Advantages ¢ Biomarker IP Trade secret algorithm ¢ ASPiRA Labs data structure and source Tailwinels * FDA process experience * Robust clinical / health economics publication pipeline © World-class clinical Headwints ¢ Payer contracting — driving rigoro

  34. Slide 34: Vermillion's Strategy: Built for the Future

    Vermillion’s Strategy: Built he Future at VRML/ FDA-cleared product Unique Category 1 CPT code (AMA) Medicare Coverage/Gap Fill Pricing IVD kit CLIA lab for LDTs Multi-modal predictive analytics Proprietary disease registry/samples Leading peer-reviewed publications QQ KR KNX JNA KN KNX JNA XR KN NN

  35. Slide 35: Conclusions

    Conclusions ¢ First of its kind, FDA-cleared multi-variate technology platform ¢ In two pivotal trials, OVA1® detected >80% cancers missed by clinical assessment'* ¢ Market leader expertise: biomarkers, algorithm development and clinical/data partnering to develop solutions ¢ Risks mitigated - Stron

  36. Slide 36: Corporate Headquarters and Investor Relations

    QVeRMILL Corporate Headquarters 12117 Bee Caves Rd. Building III, Suite 100 Austin, TX 78738 Tel: (512) 519.0400 Fax: (512) 439.6980 Investor Relations Michael Wood LifeSci Advisors LLC Tel: (646) 597 6983 [email protected]

Vermillion — Investor Presentation (January 2016) on 6ix